巨子生物去年业绩暴增,但八成多依赖可复美,研发占比下滑

南方都市报
27 Mar

玻尿酸“失宠”导致华熙生物和福瑞达掉队,“重组胶原蛋白”巨头巨子生物却迎来业绩高光。3月27日,巨子生物发布2024年业绩公告。该公司收入达到55.4亿元,同比增长57.2%,净利润20.6亿元,同比增长42.4%。不过,巨子生物对可复美这一单一品牌的依赖度进一步上升,后者贡献了八成以上的收入。同时,该公司业绩非常依赖线上直销渠道的贡献,这使得其销售及经销开支不可避免地水涨船高,因此2024年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10